Sangamo Therapeutics, Inc.
SGMOQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$30.66M
Close$
Share Statistics
| Market cap | $30.66 Million |
|---|---|
| Enterprise Value | $30.65 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -468187.69% |
|---|---|
| Return on Assets | -85789.41% |
| Return on Invested Capital | -87410.88% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.89 |
| Enterprise Value to EBIT | -0.24 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Sangamo Therapeutics Inc
142 employees
CEO: Alexander Macrae Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The firm focuses on three therapeutic areas: inherited metabolic diseases, central nervous syste...